Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers

International Journal of Clinical Oncology

Volumn 12, Issue 4, 2007, Pages 284-290

  Jiko, Mari ^a   Yano, Ikuko ^a   Sato, Eriko ^a   Takahashi, Kazushige ^a   Motohashi, Hideyuki ^a   Masuda, Satohiro ^a   Okuda, Masahiro ^a   Ito, Noriyuki ^b   Nakamura, Eijiro ^b   Segawa, Takehiko ^b   Kamoto, Toshiyuki ^b   Ogawa, Osamu ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Carboplatin; Gemcitabine; Paclitaxel; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CARBOPLATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ESTRAMUSTINE PHOSPHATE; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; LEUKOPENIA; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYTOCHROME P-450 ENZYME SYSTEM; DEOXYCYTIDINE; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; P-GLYCOPROTEIN; PACLITAXEL; POLYMORPHISM, GENETIC; PROSTATE-SPECIFIC ANTIGEN; UROGENITAL NEOPLASMS;

EID: 34547922038     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0681-y     Document Type: Article

References (37)

1. EK Rowinsky 1995 Paclitaxel (Taxol) N Engl J Med 332 1004 1014
2. PB Schiff SB Horwitz 1980 Taxol stabilizes microtubules in mouse fibroblast cells Proc Natl Acad Sci U S A 77 1561 1565
3. WK Kelly T Curley S Slovin 2001 Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer J Clin Oncol 19 44 53
4. AA Meluch FA Greco HA Burris 3rd 2001 Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network J Clin Oncol 19 3018 3024
5. L Gianni CM Kearns A Giani 1995 Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans J Clin Oncol 13 180 190
6. T Ohtsu Y Sasaki T Tamura 1995 Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-h infusion versus a 24-h infusion Clin Cancer Res 1 599 606
7. MT Huizing G Giaccone LJ van Warmerdam 1997 Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer J Clin Oncol 15 317 329
8. R Bruno R Olivares J Berille 2003 α-1-Acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel Clin Cancer Res 9 1077 1082
9. WE Evans HL McLeod 2003 Pharmacogenomics - drug disposition, drug targets, and side effects N Engl J Med 348 538 549
10. DS Sonnichen Q Liu EG Schuetz 1995 Variability in human cytochrome P450 paclitaxel metabolism J Pharmacol Exp Ther 275 566 575
11. A Sparreboom J van Asperen U Mayer 1997 Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc Natl Acad Sci U S A 94 2031 2035
12. BC Goh SC Lee LZ Wang 2002 Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies J Clin Oncol 20 3683 3690
13. M Shou M Martinet KR Korzekwa 1998 Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver Pharmacogenetics 8 391 401
14. M Goto S Masuda T Kiuchi 2004 CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation Pharmacogenetics 14 471 478
15. S Hoffmeyer O Burk O van Richter 2000 Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 3473 3478
16. RB Kim BF Leake EF Choo 2001 Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 189 199
17. M Goto S Masuda H Saito 2002 C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation Pharmacogenetics 12 451 457
18. D Dai DC Zeldin JA Blaisdell 2001 Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 597 607
19. M Nakajima Y Fujiki S Kyo 2005 Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 J Clin Pharmacol 45 674 682
20. A Henningsson S Marsh WJ Loos 2005 Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel Clin Cancer Res 11 8097 8104
21. AH Calvert DR Newell LA Gumbrell 1989 Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1748 1756
22. M Jiko I Yano M Okuda 2005 Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure Pharm Res 22 228 234
23. RH van Schaik SN de Wildt NM van Iperen 2000 CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians Clin Chem 46 1834 1836
24. RH van Schaik SN de Wildt R Brosens 2001 The CYP3A4*3 allele: is it really rare? Clin Chem 47 1104 1106
25. RH van Schaik IP vander Heiden JN van den Anker 2001 CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 1668 1671
26. Beal SL, Boeckman AJ, Sheiner LB (1982) NONMEM users guides. NONMEM Project Group, University of California, San Francisco
27. DS Sonnichsen CA Hurwitz CB Pratt 1994 Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors J Clin Oncol 12 532 538
28. JR Kroep G Giaccone DA Voorn 1999 Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer J Clin Oncol 17 2190 2197
29. TC Dowling AE Briglia JC Fink 2003 Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease Clin Pharmacol Ther 73 427 434
30. 1-acid glycoprotein Res Commun Chem Pathol Pharmacol 80 337 344
31. Y Uwai S Masuda M Goto 2004 Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients J Hum Genet 49 40 45
32. B Chowbay H Li M David 2005 Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression Br J Clin Pharmacol 60 159 171
33. JH Shon YR Yoon WS Hong 2005 Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the genetic polymorphism Clin Pharmacol Ther 78 191 201
34. M Nakajima Y Fujiki K Noda 2003 Genetic polymorphisms of CYP2C8 in Japanese population Drug Metab Dispos 31 687 690
35. K Torres SB Horwitz 1998 Mechanisms of Taxol-induced cell death are concentration dependent Cancer Res 58 3620 3626
36. MA Jordan RJ Toso D Thrower 1993 Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations Proc Natl Acad Sci U S A 90 9552 9556
37. 2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells J Clin Invest 110 91 99